Idenix Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

Universitá Degli Studi Di Cagliari

The Uab Research Foundation (the University of Alabama at Birmingham)

Centre National De La Recherche Scientifique

Other

Emory University

L'université Montpellier Ii

Biothea Pharma, Inc.

Novartis Ag

University of Georgia Research Foundation Inc

University of Cagliari

Brown University

Universitè De Montpellier

Cnrs

Jean-Pierre Sommadossi

Adel M Moussa

Gilles J Gosselin

Paulo LaColla

Raymond F Schinazi

Jean-Louis Imbach

Paolo LaColla

David N Standring

Claire Pierra

Christian Perigaud

Suzanne Peyrottes

Paolo La Colla

Martin L Bryant

Vadim Bichko

Mahmoud H El Kouni

Marino Artico

Lin Qu

Maria Seifer

Richard Storer

Chung K Chu

Gilles Gosselin

April Patty

Keith M Pietropaolo

Xiao-Jian Zhou

William M Shafer

Romano Silvestri

Chum K Chung

Poalo La Colla

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

Advantageous anti-HCV combination therapy

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

Highly active compounds against COVID-19

Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

Crystalline epinephrine malonate salt

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

β-D-2'-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

2′-substituted-N-substituted purine nucleotides for RNA virus treatment

The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

A pharmaceutical composition that includes a compound of the structure: to treat an HCV infected patient with cirrhosis, and uses thereof.

Treatment of HCV infected patients with cirrhosis

2'-substituted-N6-substituted purine nucleotides for RNA virus treatment

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Growing community of inventors

Boston, MA, United States of America

Jean-Pierre Sommadossi